

# **PHENTERMINE HYDROCHLORIDE- phentermine hydrochloride capsule Bryant Ranch Prepack**

-----

## **HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use Phentermine Hydrochloride Capsules USP safely and effectively. See full prescribing information for Phentermine Hydrochloride Capsules USP.**

## **PHENTERMINE Hydrochloride Capsules USP C IV**

**Initial U.S. Approval: 1959**

### **INDICATIONS AND USAGE**

Phentermine hydrochloride is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index  $\geq 30$  kg/m<sup>2</sup>, or  $\geq 27$  kg/m<sup>2</sup> in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (1)

The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use. (1)

### **DOSAGE AND ADMINISTRATION**

- Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2.1)
- Late evening administration should be avoided (risk of insomnia). (2.1)
- Phentermine hydrochloride capsules can be taken with or without food (2.1)
- Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup> (2.2)

### **DOSAGE FORMS AND STRENGTHS**

- Capsules containing 15 mg or 30 mg phentermine hydrochloride. (3)

### **CONTRAINDICATIONS**

- History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) (4)
- During or within 14 days following the administration of monoamine oxidase inhibitors (4)
- Hyperthyroidism (4)
- Glaucoma (4)
- Agitated states (4)
- History of drug abuse (4)
- Pregnancy (4, 8.1)
- Nursing (4, 8.3)
- Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines (4)

### **WARNINGS AND PRECAUTIONS**

- Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). (5.1)
- Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. (5.2)
- Rare cases of serious regurgitant cardiac valvular disease have been reported. (5.3)
- Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded. (5.4)
- Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. (5.5)
- Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose. (5.6)
- Concomitant alcohol use may result in an adverse drug reaction. (5.7)
- Use caution in patients with even mild hypertension (risk of increase in blood pressure). (5.8)
- A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (5.9)

## ADVERSE REACTIONS

Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (6)

**To report SUSPECTED ADVERSE REACTIONS, contact Elite Laboratories, Inc. at 1-888-852-6657 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## DRUG INTERACTIONS

- Monoamine oxidase inhibitors: Risk of hypertensive crisis. (4, 7.1)
- Alcohol: Consider potential interaction (7.2)
- Insulin and oral hypoglycemics: Requirements may be altered. (7.3)
- Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine. (7.4)

## USE IN SPECIFIC POPULATIONS

- Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. (4, 8.3)
- Pediatric use: Safety and effectiveness not established. (8.4)
- Geriatric use: Due to substantial renal excretion, use with caution. (8.5)
- Renal Impairment: Avoid use in patients with eGFR less than 15 mL/min/m<sup>2</sup> or end-stage renal disease requiring dialysis). (8.6)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 11/2023**

---

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

2.1 Exogenous Obesity

2.2 Dosage in Patients With Renal Impairment

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

5.1 Coadministration with Other Drug Products for Weight Loss

5.2 Primary Pulmonary Hypertension

5.3 Valvular Heart Disease

5.4 Development of Tolerance, Discontinuation in Case of Tolerance

5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks

5.6 Risk of Abuse and Dependence

5.7 Usage with Alcohol

5.8 Use in Patients with Hypertension

5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus

### 6 ADVERSE REACTIONS

### 7 DRUG INTERACTIONS

7.1 Monoamine Oxidase Inhibitors

7.2 Alcohol

7.3 Insulin and Oral Hypoglycemic Medications

7.4 Adrenergic Neuron Blocking Drugs

### 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

## 9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

9.2 Abuse

9.3 Dependence

## 10 OVERDOSAGE

10.1 Acute Overdosage

10.2 Chronic Intoxication

## 11 DESCRIPTION

## 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

## 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

## 14 CLINICAL STUDIES

## 16 HOW SUPPLIED/STORAGE AND HANDLING

## 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

Phentermine hydrochloride capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index  $\geq 30$  kg/m<sup>2</sup>, or  $\geq 27$  kg/m<sup>2</sup> in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

Below is a chart of body mass index (BMI) based on various heights and weights.

BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds  $\div$  2.2 = kg; inches  $\times$  0.0254 = meters.

### BODY MASS INDEX (BMI), kg/m<sup>2</sup>

| Weight<br>(pounds) | Height (feet, inches) |      |      |      |      |      |
|--------------------|-----------------------|------|------|------|------|------|
|                    | 5'0"                  | 5'3" | 5'6" | 5'9" | 6'0" | 6'3" |
| 140                | 27                    | 25   | 23   | 21   | 19   | 18   |
| 150                | 29                    | 27   | 24   | 22   | 20   | 19   |
| 160                | 31                    | 28   | 26   | 24   | 22   | 20   |
| 170                | 33                    | 30   | 28   | 25   | 23   | 21   |
| 180                | 35                    | 32   | 29   | 27   | 25   | 23   |

|     |    |    |    |    |    |    |
|-----|----|----|----|----|----|----|
| 190 | 37 | 34 | 31 | 28 | 26 | 24 |
| 200 | 39 | 36 | 32 | 30 | 27 | 25 |
| 210 | 41 | 37 | 34 | 31 | 29 | 26 |
| 220 | 43 | 39 | 36 | 33 | 30 | 28 |
| 230 | 45 | 41 | 37 | 34 | 31 | 29 |
| 240 | 47 | 43 | 39 | 36 | 33 | 30 |
| 250 | 49 | 44 | 40 | 37 | 34 | 31 |

The limited usefulness of agents of this class, including phentermine, [see *Clinical Pharmacology* (12.1, 12.2)] should be measured against possible risk factors inherent in their use such as those described below.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Exogenous Obesity

Dosage should be individualized to obtain an adequate response with the lowest effective dose.

The usual adult dose is 15 mg to 30 mg as prescribed by the physician, at approximately 2 hours after breakfast for appetite control. Administration of one 30 mg capsule daily has been found to be adequate in depression of the appetite for 12 to 14 hours. Phentermine is not recommended for use in pediatric patients  $\leq 16$  years of age.

Late evening medication should be avoided because of the possibility of resulting insomnia.

### 2.2 Dosage in Patients With Renal Impairment

The recommended maximum dosage of phentermine is 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m<sup>2</sup>). Avoid use of phentermine in patients with eGFR less than 15 mL/min/1.73m<sup>2</sup> or end-stage renal disease requiring dialysis [see *Use in Specific Populations* (8.6) and *Clinical Pharmacology* (12.3)].

## 3 DOSAGE FORMS AND STRENGTHS

Capsules containing 15 mg or 30 mg phentermine hydrochloride (equivalent to 12 mg or 24 mg phentermine base, respectively).

15 mg capsules: gray/yellow; imprinted "EL600" in black ink on cap and body, filled with white to off-white powder.

30 mg capsules: yellow; imprinted "EL601" in black ink on cap and body, filled with white to off-white powder.

## 4 CONTRAINDICATIONS

- History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)
- During or within 14 days following the administration of monoamine oxidase inhibitors

- Hyperthyroidism
- Glaucoma
- Agitated states
- History of drug abuse
- Pregnancy [see *Use in Specific Populations (8.1)*]
- Nursing [see *Use in Specific Populations (8.3)*]
- Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Coadministration with Other Drug Products for Weight Loss

**Phentermine hydrochloride capsules are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.**

### 5.2 Primary Pulmonary Hypertension

**Primary Pulmonary Hypertension (PPH) - a rare, frequently fatal disease of the lungs - has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone.** The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.

### 5.3 Valvular Heart Disease

**Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.**

### 5.4 Development of Tolerance, Discontinuation in Case of Tolerance

When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be

discontinued.

### **5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks**

Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

### **5.6 Risk of Abuse and Dependence**

Phentermine is related chemically and pharmacologically to amphetamine (d- and d/l-amphetamine) and to other related stimulant drugs that have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See *Drug Abuse and Dependence (9)* and *Overdosage (10)*.

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

### **5.7 Usage with Alcohol**

Concomitant use of alcohol with phentermine may result in an adverse drug reaction.

### **5.8 Use in Patients with Hypertension**

Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).

### **5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus**

A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.

## **6 ADVERSE REACTIONS**

The following adverse reactions are described, or described in greater detail, in other sections:

- Primary pulmonary hypertension [see *Warnings and Precautions (5.2)*]
- Valvular heart disease [see *Warnings and Precautions (5.3)*]
  - Effect on the ability to engage in potentially hazardous tasks [see *Warnings and Precautions (5.5)*]
- Withdrawal effects following prolonged high dosage administration [see *Drug Abuse and Dependence (9.3)*]

The following adverse reactions to phentermine have been identified:

#### Cardiovascular

Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.

## Central Nervous System

Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.

## Gastrointestinal

Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

## Allergic

Urticaria.

## Endocrine

Impotence, changes in libido.

## **7 DRUG INTERACTIONS**

### **7.1 Monoamine Oxidase Inhibitors**

Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.

### **7.2 Alcohol**

Concomitant use of alcohol with phentermine may result in an adverse drug reaction.

### **7.3 Insulin and Oral Hypoglycemic Medications**

Requirements may be altered [see *Warnings and Precautions (5.9)*].

### **7.4 Adrenergic Neuron Blocking Drugs**

Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### *Pregnancy Category X*

Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and d,l-amphetamine) [see *Clinical Pharmacology (12.1)*]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

### **8.3 Nursing Mothers**

It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

### **8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.

### **8.5 Geriatric Use**

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

### **8.6 Renal Impairment**

Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment [see *Clinical Pharmacology* (12.3)].

Use caution when administering phentermine to patients with renal impairment. In patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m<sup>2</sup>), limit the dosage of phentermine to 15 mg daily [see *Dosage and Administration* (2.2)]. Phentermine has not been studied in patients with eGFR less than 15 mL/min/1.73m<sup>2</sup>, including end-stage renal disease requiring dialysis; avoid use in these populations.

## **9 DRUG ABUSE AND DEPENDENCE**

### **9.1 Controlled Substance**

Phentermine is a Schedule IV controlled substance.

### **9.2 Abuse**

Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.

### **9.3 Dependence**

Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt



cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

## **10 OVERDOSAGE**

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose.

### **10.1 Acute Overdosage**

Manifestations of acute overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdose of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.


Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine®, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdose.

### **10.2 Chronic Intoxication**

Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See *Drug Abuse and Dependence* (9.3).

## **11 DESCRIPTION**

Phentermine hydrochloride is a sympathomimetic amine anorectic. Its chemical name is  $\alpha,\alpha$ ,-dimethylphenethylamine hydrochloride. The structural formula is as follows:



Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.

Phentermine hydrochloride capsules USP is available as an oral capsule containing 15 mg or 30 mg of phentermine hydrochloride (equivalent to 12 mg or 24 mg of phentermine base).

Each phentermine hydrochloride capsule contains the following inactive ingredients: starch 1500, lactose monohydrate and magnesium stearate. Phentermine hydrochloride capsules 15 mg also contain D&C yellow No. 10, FD&C red No. 3, FD&C blue No 1, FD&C red No. 40, gelatin and titanium dioxide. Phentermine hydrochloride capsules 30 mg also contain D&C yellow No. 10, FD&C red No. 3, gelatin and titanium dioxide. The imprinting ink for the capsules contains the following ingredients: shellac glaze in ethanol, iron oxide black, n-butyl alcohol, propylene glycol, SDA 3A alcohol, methanol, FD&C blue No. 2, FD&C red No. 40, FD &C blue No. 1, and D&C yellow No. 10.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.

### 12.2 Pharmacodynamics

Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

### 12.3 Pharmacokinetics

Following the administration of phentermine, phentermine reaches peak concentrations ( $C_{max}$ ) after 3 to 4.4 hours.

#### Specific Populations

## *Renal Impairment*

Cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions was 62%-85%.

Systemic exposure of phentermine may increase up to 91%, 45%, and 22% in patients with severe, moderate, and mild renal impairment, respectively [see *Dosage and Administration (2.2) and Use in Specific Populations (8.6)*].

## Drug Interactions

In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine C<sub>max</sub> and AUC increase 13% and 42%, respectively.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.

## **14 CLINICAL STUDIES**

In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with "anorectic" drugs lost more weight on the average than those treated with placebo and diet.

The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks' duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **Phentermine hydrochloride capsules, USP**

**30 mg capsules**, yellow; imprinted "EL601" in black ink on cap and body, filled with white to off-white powder.

Product: 71335-0030

NDC: 71335-0030-0 24 CAPSULE in a BOTTLE

NDC: 71335-0030-1 30 CAPSULE in a BOTTLE

NDC: 71335-0030-2 7 CAPSULE in a BOTTLE

NDC: 71335-0030-3 14 CAPSULE in a BOTTLE

NDC: 71335-0030-4 56 CAPSULE in a BOTTLE

NDC: 71335-0030-5 60 CAPSULE in a BOTTLE

NDC: 71335-0030-6 2 CAPSULE in a BOTTLE

NDC: 71335-0030-7 21 CAPSULE in a BOTTLE

NDC: 71335-0030-8 28 CAPSULE in a BOTTLE

NDC: 71335-0030-9 42 CAPSULE in a BOTTLE

**15 mg capsules**, gray/yellow; imprinted "EL600" in black ink on cap and body, filled with white to off-white powder.

Product: 71335-0419

NDC: 71335-0419-1 7 CAPSULE in a BOTTLE

NDC: 71335-0419-2 14 CAPSULE in a BOTTLE

NDC: 71335-0419-3 30 CAPSULE in a BOTTLE

NDC: 71335-0419-4 100 CAPSULE in a BOTTLE

NDC: 71335-0419-5 2 CAPSULE in a BOTTLE

NDC: 71335-0419-6 28 CAPSULE in a BOTTLE

NDC: 71335-0419-7 90 CAPSULE in a BOTTLE

NDC: 71335-0419-8 21 CAPSULE in a BOTTLE

NDC: 71335-0419-9 60 CAPSULE in a BOTTLE

NDC: 71335-0419-0 45 CAPSULE in a BOTTLE

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).

Keep out of the reach of children.

Repackaged/Relabeled by:

Bryant Ranch Prepack, Inc.

Burbank, CA 91504

## **17 PATIENT COUNSELING INFORMATION**

Patients must be informed that phentermine hydrochloride is a *short-term* (a few weeks)

adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [see *Indications and Usage (1)* and *Warnings and Precautions (5.1)*].

Patients must be instructed on how much phentermine to take, and when and how to take it [see *Dosage and Administration (2)*].

Advise pregnant women and nursing mothers not to use phentermine (see *Use in Specific Populations (8.1, 8.3)*).

Patients must be informed about the risks of use of phentermine (including the risks discussed in *Warnings and Precautions*), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:

- Development of primary pulmonary hypertension [see *Warnings and Precautions (5.2)*]
- Development of serious valvular heart disease [see *Warnings and Precautions (5.3)*]
- Effects on the ability to engage in potentially hazardous tasks [see *Warnings and Precautions (5.5)*]
- The risk of an increase in blood pressure [see *Warnings and Precautions (5.8)* and *Adverse Reactions (6)*]
- The risk of interactions [see *Contraindications (4)*, *Warnings and Precautions (5.7, 5.9)* and *Drug Interactions (7)*]

See also, for example, *Adverse Reactions (6)* and *Use in Specific Populations (8)*.

The patients must also be informed about

- the potential for developing tolerance and actions if they suspect development of tolerance [see *Warnings and Precautions (5.4)*] and
- the risk of dependence and the potential consequences of abuse [see *Warnings and Precautions (5.6)*, *Drug Abuse and Dependence (9)*, and *Overdosage (10)*].

Tell patients to keep phentermine in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.

For inquiries call TAGI Pharma, Inc. at 1-855-225-8244 or e-mail [druginfo@tagipharma.com](mailto:druginfo@tagipharma.com)

Manufactured by:  
Elite Laboratories, Inc.  
Northvale, NJ 07647

Distributed by:  
TAGI Pharma  
South Beloit, IL 61080

Revised May 2019  
IN0501

**Phentermine HCl 30mg (CIV) Capsule**



GTIN 00371335003012  
 Lot 208820  
 Exp 11/29/2025  
 SN 0123456789

Each capsule contains: Phentermine Hydrochloride, USP 30 mg (equivalent to 24 mg of phentermine base).

Keep this and all medication out of the reach of children.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed. Protect from moisture.

Do not accept if seal over bottle opening is broken or missing.

Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.

NDC 71335-0030-1

**Phentermine Hydrochloride Capsules, USP**



**30 mg**



Repackaged by:  
 Bryant Ranch Prepack, Inc.  
 Burbank, CA 91504 USA

Rx only  
**30 Capsules**

Manufactured by:  
 Elite Laboratories Inc.



**Phentermine HCL 15mg (CIV) Capsule**



GTIN 00371335041915  
 Lot 208820  
 Exp 11/29/2025  
 SN 0123456789

Each capsule contains: Phentermine Hydrochloride, USP 15 mg (equivalent to 12 mg of phentermine base).

Keep this and all medication out of the reach of children.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed. Protect from moisture.

Do not accept if seal over bottle opening is broken or missing.

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

NDC 71335-0419-1

**Phentermine Hydrochloride Capsules, USP**



**15 mg**



Repackaged by:  
 Bryant Ranch Prepack, Inc.  
 Burbank, CA 91504 USA

Rx only  
**7 Capsules**

Manufactured by:  
 Elite Laboratories Inc.



**PHENTERMINE HYDROCHLORIDE**

phentermine hydrochloride capsule

**Product Information**

|                                |                         |                           |                               |
|--------------------------------|-------------------------|---------------------------|-------------------------------|
| <b>Product Type</b>            | HUMAN PRESCRIPTION DRUG | <b>Item Code (Source)</b> | NDC:71335-0030(NDC:51224-202) |
| <b>Route of Administration</b> | ORAL                    | <b>DEA Schedule</b>       | CIV                           |

**Active Ingredient/Active Moiety**

| Ingredient Name                                                                     | Basis of Strength         | Strength |
|-------------------------------------------------------------------------------------|---------------------------|----------|
| <b>PHENTERMINE HYDROCHLORIDE</b> (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP) | PHENTERMINE HYDROCHLORIDE | 30 mg    |

**Inactive Ingredients**

| Ingredient Name                         | Strength |
|-----------------------------------------|----------|
| LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  |          |
| MAGNESIUM STEARATE (UNII: 70097M6I30)   |          |
| STARCH, TAPIOCA (UNII: 24SC3U704I)      |          |
| D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)    |          |
| FD&C RED NO. 3 (UNII: PN2ZH5LOQY)       |          |
| TITANIUM DIOXIDE (UNII: 15FIX9V2JP)     |          |
| GELATIN, UNSPECIFIED (UNII: 2G86QN327L) |          |

### Product Characteristics

|          |         |              |          |
|----------|---------|--------------|----------|
| Color    | YELLOW  | Score        | no score |
| Shape    | CAPSULE | Size         | 16mm     |
| Flavor   |         | Imprint Code | EL601    |
| Contains |         |              |          |

### Packaging

| #  | Item Code        | Package Description                               | Marketing Start Date | Marketing End Date |
|----|------------------|---------------------------------------------------|----------------------|--------------------|
| 1  | NDC:71335-0030-2 | 7 in 1 BOTTLE; Type 0: Not a Combination Product  | 12/06/2013           |                    |
| 2  | NDC:71335-0030-8 | 28 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 3  | NDC:71335-0030-5 | 60 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 4  | NDC:71335-0030-6 | 2 in 1 BOTTLE; Type 0: Not a Combination Product  | 12/06/2013           |                    |
| 5  | NDC:71335-0030-0 | 24 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 6  | NDC:71335-0030-9 | 42 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 7  | NDC:71335-0030-3 | 14 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 8  | NDC:71335-0030-4 | 56 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 9  | NDC:71335-0030-1 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |
| 10 | NDC:71335-0030-7 | 21 in 1 BOTTLE; Type 0: Not a Combination Product | 12/06/2013           |                    |

### Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|------------------------------------------|----------------------|--------------------|
| ANDA               | ANDA202248                               | 02/17/2012           |                    |

## PHENTERMINE HYDROCHLORIDE

phentermine hydrochloride capsule

**Product Information**

|                                |                         |                           |                               |
|--------------------------------|-------------------------|---------------------------|-------------------------------|
| <b>Product Type</b>            | HUMAN PRESCRIPTION DRUG | <b>Item Code (Source)</b> | NDC:71335-0419(NDC:51224-203) |
| <b>Route of Administration</b> | ORAL                    | <b>DEA Schedule</b>       | CIV                           |

**Active Ingredient/Active Moiety**

| <b>Ingredient Name</b>                                                              | <b>Basis of Strength</b>  | <b>Strength</b> |
|-------------------------------------------------------------------------------------|---------------------------|-----------------|
| <b>PHENTERMINE HYDROCHLORIDE</b> (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP) | PHENTERMINE HYDROCHLORIDE | 15 mg           |

**Inactive Ingredients**

| <b>Ingredient Name</b>                          | <b>Strength</b> |
|-------------------------------------------------|-----------------|
| <b>LACTOSE MONOHYDRATE</b> (UNII: EWQ57Q8I5X)   |                 |
| <b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)    |                 |
| <b>STARCH, TAPIOCA</b> (UNII: 24SC3U704I)       |                 |
| <b>D&amp;C YELLOW NO. 10</b> (UNII: 35SW5USQ3G) |                 |
| <b>FD&amp;C RED NO. 3</b> (UNII: PN2ZH5LOQY)    |                 |
| <b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)      |                 |
| <b>GELATIN, UNSPECIFIED</b> (UNII: 2G86QN327L)  |                 |
| <b>FD&amp;C BLUE NO. 1</b> (UNII: H3R47K3TBD)   |                 |
| <b>FD&amp;C RED NO. 40</b> (UNII: WZB9127XOA)   |                 |

**Product Characteristics**

|                 |              |                     |          |
|-----------------|--------------|---------------------|----------|
| <b>Color</b>    | YELLOW, GRAY | <b>Score</b>        | no score |
| <b>Shape</b>    | CAPSULE      | <b>Size</b>         | 16mm     |
| <b>Flavor</b>   |              | <b>Imprint Code</b> | EL600    |
| <b>Contains</b> |              |                     |          |

**Packaging**

| <b>#</b> | <b>Item Code</b> | <b>Package Description</b>                        | <b>Marketing Start Date</b> | <b>Marketing End Date</b> |
|----------|------------------|---------------------------------------------------|-----------------------------|---------------------------|
| 1        | NDC:71335-0419-0 | 45 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 2        | NDC:71335-0419-7 | 90 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 3        | NDC:71335-0419-8 | 21 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 4        | NDC:71335-0419-2 | 14 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 5        | NDC:71335-0419-5 | 2 in 1 BOTTLE; Type 0: Not a Combination Product  | 10/16/2014                  |                           |
| 6        | NDC:71335-0419-6 | 28 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 7        | NDC:71335-0419-9 | 60 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| 8        | NDC:71335-0419-3 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |



|                              |                                                 |                                                    |                             |                           |
|------------------------------|-------------------------------------------------|----------------------------------------------------|-----------------------------|---------------------------|
| <b>9</b>                     | NDC:71335-0419-4                                | 100 in 1 BOTTLE; Type 0: Not a Combination Product | 10/16/2014                  |                           |
| <b>10</b>                    | NDC:71335-0419-1                                | 7 in 1 BOTTLE; Type 0: Not a Combination Product   | 10/16/2014                  |                           |
| <b>Marketing Information</b> |                                                 |                                                    |                             |                           |
| <b>Marketing Category</b>    | <b>Application Number or Monograph Citation</b> |                                                    | <b>Marketing Start Date</b> | <b>Marketing End Date</b> |
| ANDA                         | ANDA202248                                      |                                                    | 02/17/2012                  |                           |

**Labeler** - Bryant Ranch Prepack (171714327)

|                      |                |               |                                                                  |
|----------------------|----------------|---------------|------------------------------------------------------------------|
| <b>Establishment</b> |                |               |                                                                  |
| <b>Name</b>          | <b>Address</b> | <b>ID/FEI</b> | <b>Business Operations</b>                                       |
| Bryant Ranch Prepack |                | 171714327     | REPACK(71335-0419, 71335-0030) , RELABEL(71335-0030, 71335-0419) |

Revised: 11/2023

Bryant Ranch Prepack